| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
77,400,000 |
| Market
Cap: |
687.31(M) |
| Last
Volume: |
924,004 |
Avg
Vol: |
1,535,793 |
| 52
Week Range: |
$4.32 - $9.91 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security markets. Co.'s primary product, TPOXX®, is a U.S. Food & Drug Administration-approved oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Antal James |
|
• • – |
2019-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
160,875 |
|
- |
|
| Plansky Michael C. |
|
• • – |
2019-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
30,000 |
|
- |
|
| Marshall Joseph W Iii |
|
• • – |
2019-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
142,769 |
|
- |
|
| Bayer Michael J |
|
• • – |
2019-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
134,744 |
|
- |
|
| Savas Paul G |
|
• • – |
2019-05-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
252,847 |
|
- |
|
| Marshall Joseph W Iii |
|
• • – |
2019-01-09 |
4 |
D |
$7.78 |
$118,497 |
D/D |
(15,231) |
127,769 |
|
- |
|
| Marshall Joseph W Iii |
|
• • – |
2019-01-09 |
4 |
OE |
$4.74 |
$118,500 |
D/D |
25,000 |
143,000 |
|
- |
|
| Luckshire Daniel J |
Executive VP & CFO |
• • – |
2018-12-12 |
4 |
D |
$6.38 |
$182,557 |
D/D |
(28,614) |
206,065 |
|
- |
|
| Luckshire Daniel J |
Executive VP & CFO |
• • – |
2018-12-12 |
4 |
OE |
$3.53 |
$208,146 |
D/D |
58,965 |
234,679 |
|
- |
|
| Gomez Phillip Louis Iii |
Chief Executive Officer |
• • – |
2018-11-22 |
4 |
D |
$5.55 |
$1,595,864 |
D/D |
(287,543) |
315,693 |
|
- |
|
| Gomez Phillip Louis Iii |
Chief Executive Officer |
• • – |
2018-11-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
588,236 |
603,236 |
|
- |
|
| Rose Eric A Md |
|
• • – |
2018-11-22 |
4 |
D |
$5.55 |
$587,723 |
D/D |
(105,896) |
993,094 |
|
- |
|
| Rose Eric A Md |
|
• • – |
2018-11-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
200,000 |
1,098,990 |
|
- |
|
| Savas Paul G |
|
• • – |
2018-11-16 |
4 |
B |
$5.58 |
$27,900 |
D/D |
5,000 |
237,847 |
0.01 |
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• • – |
2018-11-13 |
4 |
S |
$5.29 |
$164,514 |
D/D |
(31,099) |
197,465 |
|
- |
|
| Gomez Phillip Louis Iii |
Chief Executive Officer |
• • – |
2018-11-12 |
4 |
B |
$5.20 |
$78,000 |
D/D |
15,000 |
15,000 |
0.01 |
- |
|
| Savas Paul G |
|
• • – |
2018-11-12 |
4 |
B |
$5.01 |
$50,100 |
D/D |
10,000 |
232,847 |
0.01 |
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• • – |
2018-11-12 |
4 |
S |
$4.96 |
$93,749 |
D/D |
(18,901) |
228,564 |
|
- |
|
| Bayer Michael J |
|
• • – |
2018-10-16 |
4 |
D |
$5.32 |
$78,502 |
D/D |
(14,756) |
119,744 |
|
- |
|
| Bayer Michael J |
|
• • – |
2018-10-16 |
4 |
OE |
$3.14 |
$78,500 |
D/D |
25,000 |
134,500 |
|
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• • – |
2018-09-11 |
4 |
D |
$7.16 |
$385,559 |
D/D |
(53,849) |
247,465 |
|
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• • – |
2018-09-11 |
4 |
OE |
$0.00 |
$299,154 |
D/D |
93,174 |
259,640 |
|
- |
|
| Rose Eric A Md |
Executive Chairman |
• • – |
2018-08-20 |
4 |
D |
$7.98 |
$1,869,530 |
D/D |
(234,277) |
898,990 |
|
- |
|
| Rose Eric A Md |
Executive Chairman |
• • – |
2018-08-20 |
4 |
OE |
$2.49 |
$996,000 |
D/D |
400,000 |
1,133,267 |
|
- |
|
| Abrams Robin Elizabeth |
General Counsel and CAO |
• • – |
2018-08-20 |
4 |
D |
$7.98 |
$55,748 |
D/D |
(6,986) |
8,014 |
|
- |
|
355 Records found
|
|
Page 4 of 15 |
|
|
0.07 (0.79%) 
